Drug Database
VA

varicella zoster vaccine

✓ Approved

HK inno.N · Vaccine · Vaccine

What is varicella zoster vaccine?

varicella zoster vaccine is a vaccine developed by HK inno.N. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyHK inno.N
Drug ClassVaccine, Large Molecules
RouteInjectable (Others)
StatusApproved

Therapeutic Indications

varicella zoster vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsVaricella zoster virus infection✓ Approved

Related Research Articles

PubMedCurrent medical imaging2026-06-09

Concurrent Spinal Dural Arteriovenous Fistula and Varicella-Zoster Virus Meningoencephalitis Unmasked by Corticosteroid-Associated Deterioration: A Case Report on the Diagnostic Value of Serial mNGS.

Hao Mengdi M, Sha Yuhui Y, Gao Jun J, Niu Jingwen J et al.

Concurrent spinal dural arteriovenous fistula (SDAVF) and varicella-zoster virus (VZV) meningoencephalitis are exceptionally rare, and overlapping features can delay diagnosis. This case adds to the literature by illustrating how corticosteroid exposure before exclusion of vascular and infectious mimics may be followed by neurological deterioration, and by emphasizing the diagnostic value of serial metagenomic next-generation sequencing (mNGS). A 48-year-old man developed insidious bilateral lower-limb weakness that progressed to numbness, sphincter dysfunction, and near-paralysis. Initial spinal magnetic resonance imaging showed diffuse thoracolumbar cord lesions; cerebrospinal fluid studies were mildly inflammatory, and myelitis was suspected. He received methylprednisolone pulse therapy followed by oral corticosteroids without improvement. One month later, he presented with fever, severe headache, vomiting, worsening paralysis, and altered mental status. Cerebrospinal fluid demonstrated marked pleocytosis, hypoglycorrhachia, and elevated protein, and mNGS detected abundant VZV sequences. Brain imaging showed hydrocephalus, meningeal enhancement, multifocal ischemic lesions, and intracranial arterial stenoses, consistent with VZV meningoencephalitis and vasculopathy. After external ventricular drainage, intravenous acyclovir, dexamethasone for cerebral edema, and empirical anti-tuberculosis therapy, serial mNGS showed a reduced VZV burden. Repeat spinal imaging revealed tortuous perimedullary vessels and hemosiderin deposition, and angiography confirmed SDAVF from the left T10 intercostal artery. The fistula was coagulated. At 12-month follow-up, he regained slight right-leg movement and partial sensory recovery above L1. Progressive myelopathy with atypical inflammatory features should prompt vascular evaluation and pathogen testing. Serial mNGS can identify coexisting infection, guide therapy, and help avoid hazardous empirical corticosteroid use when the diagnosis remains uncertain.

PubMedRheumatology (Oxford, England)2026-06-09

Prospective evaluation of recombinant Herpes zoster vaccine in systemic sclerosis: immunogenicity, safety, and disease outcomes.

Luppino-Assad Ana Paula AP, Mello Renata P RP, Medeiros-Ribeiro Ana Cristina AC, Aikawa Nadia E NE et al.

to evaluate humoral immune response to recombinant zoster vaccine(RZV) in immunosuppressed patients with systemic sclerosis(SSc) compared with healthy controls, to identify factors influencing vaccine response, and to assess RZV safety and impact on patient-reported outcome measures(PROMs) and disease activity(DA). A sub-analysis of a randomized, double-blind, placebo-controlled trial included 76 immunosuppressed SSc patients and 304 healthy controls(CG) receiving two RZV doses. SSc patients were randomized to receive two initial doses of RZV or placebo; after unblinding, the placebo group received two doses of RZV. Anti-glycoprotein-E antibodies were measured at baseline and six-weeks post-second dose. Geometric mean concentrations(GMCs) and factor increase(FI) were calculated. Cell-mediated immunogenicity (CMI) was evaluated. DA and PROMs were assessed using standardized instruments. Body mass index(BMI) defined nutritional status. SSc patients(47.4%diffuse/52.6%limited) were younger(53.0 vs 55.0 years, p= 0.002) and had lower BMI(p= 0.005) than CG. Humoral response were significantly lower in SSc compared with controls(92.6% vs 99.7%,p= 0.001). SSc patients showed significantly lower GMC(5.81 vs 12.6, p< 0.001) and FI(31.0 vs 59.4, p< 0.001) than controls, with comparable CMI(p> 0.05). Disease subtypes, demographic factors, immunosuppressive therapies or nutritional status did not predict impaired vaccine response(p> 0.05). Local adverse events were reduced in SSc patients(73.7% vs 86.5%,p= 0.024), while systemic reactions were comparable overall(59.2% vs 61.5%,p= 0.712). DA and PROMs outcomes remained stable(p> 0.05). RZV was well tolerated. Despite the high seroconversion rate, the immune response was significantly lower in magnitude compared with controls, without triggering DA or worsening PROMs. ∼50% lower antibody concentrations in SS raise concerns about long-term protection, underscoring the need for ongoing monitoring. ClinicalTrials.gov; NCT05879419.

PubMedVirology2026-06-09

Autophagy in VZV infection: To degrade, or to deliver?

Shen Zujie Z, Xia Ningshao N, Cheng Tong T, Wang Wei W

Varicella-zoster virus (VZV) interacts with autophagy in a manner distinct from that of many other herpesviruses. Rather than broadly blocking autophagic flux, VZV generally induces a functional autophagic response and appears to use this pathway to support productive infection. Available data suggest that autophagy mainly plays a pro-viral role during the VZV lytic cycle in epithelial cells and fibroblasts by promoting viral glycoprotein maturation, secondary envelopment, intracellular trafficking, and egress. However, emerging evidence indicates that autophagy can exert antiviral and protective effects in neuronal cells and hematopoietic cells, highlighting the cell-type-dependent duality of autophagy in VZV infection. A notable feature of this process is the convergence of autophagic and endosomal pathways, through which VZV redirects autophagy-related vesicle trafficking away from lysosomal degradation and toward transport and exocytosis. Mechanistically, ER stress-UPR signaling acts as a major upstream regulator of VZV-induced autophagy, while the contributions of mTOR, ESCRT, and TLR-related pathways remain to be fully elucidated. This review summarizes recent advances in the mechanisms, functions, and cell-context dependence of VZV-autophagy interactions and highlights key unresolved questions relevant to viral pathogenesis and host-directed antiviral strategies.

PubMedBMC infectious diseases2026-06-09

Epidemiological characteristics of varicella in Xuzhou from 2015 to 2024: surveillance study.

Jin Ge G, Song Xiaozhe X, Lou Heqing H, Sun Yonghong Y et al.

Varicella remains a major public health challenge in China, with limited evidence on long-term urban-rural epidemiological trends. This study analyzes varicella characteristics in Xuzhou, Jiangsu, 2015-2024, focusing on incidence, seasonality, and public health emergency events (PHEEs). This surveillance study analyzed population-based varicella case data and public health emergency events (PHEEs) in Xuzhou City, China, from January 2015 to December 2024. Data were extracted from the China Disease Prevention and Control Information System and the National Notifiable Disease Reporting System. Varicella PHEEs were defined as ≥ 10 cases occurring in a collective unit within one week. We employed descriptive statistics, chi-square tests, and chi-square trend tests (for temporal trends of incidence rates) to analyze temporal trends and demographic distribution; the Mann-Kendall trend test was used to assess trends in PHEE-related indicators (duration, reporting latency, and case counts per event). Annual incidence increased sharply to a peak of 65.01 per 100,000 in 2019, decreased in 2020, transiently rebounded in 2021, and then showed an overall declining pattern through 2024; overall, annual incidence varied significantly over the 10-year period (trend χ2 = 6789.65, p < 0.001). Two peaks emerged: a winter peak (Oct-Jan, 52.74% of cases) and a minor early summer peak (May-Jul, 26.36%). Urban areas had higher case counts but lower attack rates than rural areas (1.52% vs. 1.81%, p < 0.001). Males had an incidence rate 1.24 times that of females (p < 0.001). Children aged 0-14 years accounted for 83.22% of cases, with the highest rate in 5-9-year-olds (219.26/100,000), while adults aged ≥ 30 years showed a significant upward trend in case proportion (trend χ2 = 260.09, p < 0.01). All reported varicella PHEEs emerged in educational sites, 90.29% in primary schools and kindergartens, with 67.96% involving 10-30 cases. Kindergartens had the highest attack rate (5.60%). PHEE duration, case count, and reporting latency correlated strongly (Spearman's ρ=0.97-0.99, p < 0.01). Xuzhou's varicella epidemiology features seasonal clustering, age-specific vulnerability, and school-associated outbreaks. Strengthening rural/childhood vaccination and improving school PHEE responses are critical for control. Not applicable.

PubMedHealth promotion international2026-06-09

Attitudes to mandatory COVID-19 vaccination in early life: findings from the multi-country cross-sectional CANDOUR study.

Porter Georgia G, Roope Laurence S J LSJ, Violato Mara M, Duch Raymond R et al.

We examined variation in attitude toward mandatory COVID-19 vaccination in early life by sociodemographic characteristics, personal COVID-19 experience, health risk attitude, political ideology, and other COVID-19 vaccine mandate attitudes. For this purpose, we used data from 19 928 participants from 16 countries surveyed in March-November 2022 for the second wave of the COVID-19 vaccine preference and opinion survey (CANDOUR). Analyses were adjusted for poststratification weighting. Participants who disagreed with early life mandatory COVID-19 vaccination were more likely to decline vaccination against COVID-19 (14.5%) compared with those who were neutral (1.8%) and those who agreed (0.5%). Disagreement with early life mandatory vaccination was associated with more unwillingness to take risks with their own health, being centre or left-wing on the left-right political spectrum, believing COVID-19 vaccination should be a personal choice, and being opposed to vaccine mandates for schoolchildren and the public. Neutrality or agreement with early life mandatory vaccination was associated with neutrality or agreement with a vaccine mandate for schoolchildren or a governmental COVID-19 vaccine mandate for everybody. Pandemic preparedness governance needs to focus on attitudes toward vaccine mandates. Further research and commitment by governments at various levels are needed to identify social, cultural, and system-level factors that could inform vaccination strategies to be implemented for the next pandemic.

PubMedTropical medicine and health2026-06-09

Persistence and booster response of rabies antibodies among health care workers with multiple vaccinations.

Castellano Mark Joseph MJ, Sornillo Johanna Beulah JB, Saito Nobuo N, Nishizono Akira A et al.

Rabies is a fatal but vaccine-preventable disease. Health care workers (HCWs) in endemic areas may receive repeated rabies vaccination because of occupational exposure, yet data on long-term antibody persistence and booster response after multiple prior vaccine regimens remain limited. This study aimed to determine the rabies antibody profile of HCWs previously vaccinated with rabies vaccine. We analyzed 126 HCWs from the Research Institute for Tropical Medicine (RITM) and Muntinlupa Animal Bite Treatment Centers (ABTCs) in the Philippines. Vaccination records were reviewed, and booster doses consisting of 0.1 mL purified Vero cell rabies vaccine (PVRV) were administered intradermally on days 0 and 3. Pre- and post-booster rabies antibody levels were measured using the rapid fluorescent focus inhibition test (RFFIT). All HCWs vaccinated within the previous year retained pre-booster antibody titers ≥ 0.5 IU/mL. Participants who had received three or more prior rabies vaccine regimens also maintained protective pre-booster antibody levels within 3-5 years after the last vaccination. After booster administration, all participants achieved antibody titers above the protective threshold ≥ 0.5 IU/mL, regardless of prior vaccination history or time since last vaccination. Repeated rabies vaccination was linked to sustained antibody persistence, while previous vaccination history was associated with preserved booster responsiveness among HCWs. These findings suggest that, in addition to time since last vaccination, the number of prior rabies vaccine regimens may help inform about the persistence of protective antibody levels in previously immunized individuals.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about varicella zoster vaccine